End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
137 TWD | -2.49% | +13.22% | -25.34% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.34% | 611M | - | ||
+22.69% | 43.81B | B- | ||
+25.56% | 23.01B | B+ | ||
+18.00% | 15.27B | - | ||
+8.91% | 13.68B | B+ | ||
+42.72% | 11.96B | B | ||
-7.49% | 6.98B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+13.26% | 5.59B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6620 Stock
- Ratings Handa Pharmaceuticals, Inc.